The receptor-activator of nuclear kappaB ligand (RANKL) signaling pathway plays an important role in the regulation of bone growth and mediates the formation and activation of osteoclasts. Osteoclasts are involved in significant bone resorption and destruction. Denosumab is a fully human monoclonal antibody against RANKL that specifically inhibits osteoclast differentiation and bone resorption....

The study was aimed at evaluating therapeutic efficacy of vitamin D3 (VD3, 1000 IU/kg b.w., 30 days) and sodium salt methylenebisphosphonic acid (MBPA, 17 mg/kg monotherapies as well their effect in combination preventing mineral metabolism bone remodeling disturbances associated with glucocorticoid(GC)-induced osteoporosis. Osteoporosis rats induced by long-term (30 administration the syntheti...

Cystic fibrosis (CF) -related bone disease (CFBD) is an important complication of CF, and low BMD in childhood a precursor CFBD. Here, we aimed to investigate turnover biomarkers, including osteocalcin (OC), receptor activator nuclear factor kappa B ligand (RANKL) osteoprotegerin (OPG) relation children with CF (cwCF). We also evaluated factors which could affect particular emphasis on free fat...

Vascular calcification commonly associated with several pathologies and it has been suggested to be similar to bone mineralization. The axis RANKL-OPG (receptor activator of nuclear factor B ligand–osteoprotegerin) finely controls bone turnover. RANKL has been suggested to increase vascular calcification, but direct evidence is missing. Thus, in the present work, we assess the effect of RANKL i...

background: osteoclastogenesis is coordinated by the interaction of members of the tumor necrosis factor (tnf) superfamily: receptor activator of nuclear factor-κb ligand (rankl) and osteoprotegerin (opg). the aim of this study was to compare the effect of two different types of non-steroidal anti-infl ammatory drugs (nsaids) on the rankl/opg balance during the healing of the alveolar process. ...

Paget's disease is characterized by highly localized areas of increased osteoclast (OCL) activity. This suggests that the microenvironment in pagetic lesions is highly osteoclastogenic, or that OCL precursors in these lesions are hyperresponsive to osteoclastogenic factors (or both). To examine these possibilities, we compared RANK ligand (RANKL) mRNA expression in a marrow stromal cell line de...

Acting through its cognate receptor, receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL) is an essential mediator of osteoclast function and survival. Preclinical data have now firmly established that blockade of tumor-induced osteoclastogenesis by RANKL inhibition will not only protect against bone destruction but will also inhibit the progression of established bone metastases...

Receptor activator of NF-kappaB ligand (RANKL), produced by osteoblastic lineage cells and activated T cells, is an essential factor for osteoclast differentiation, activation, and survival. Therefore, RANKL is a focal point of therapies targeting bone diseases where there is an imbalance of bone metabolism in favor of bone resorption. The present study assesses the effects of exogenous RANKL o...

Two highly interesting papers related to osteoclastic activation in multiple myeloma were published in the December 15 issue of Blood.1,2 These studies were related to the imbalance of 2 molecules involved in the regulation of bone resorption: receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin. Croucher and colleagues2 found that mouse myeloma cells expressed RANKL mRNA and that...